Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Operating Expenses (2019 - 2026)

InMed Pharmaceuticals has reported Operating Expenses over the past 5 years, most recently at $2.3 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 15.77% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $9.2 million, down 3.73%, while the annual FY2025 figure was $9.7 million, 3.83% up from the prior year.
  • Operating Expenses for Q4 2025 was $2.3 million at InMed Pharmaceuticals, up from $2.2 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $6.8 million in Q2 2022 and troughed at $2.0 million in Q4 2023.
  • A 5-year average of $2.8 million and a median of $2.4 million in 2022 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: tumbled 69.64% in 2023 and later soared 37.88% in 2024.
  • Year by year, Operating Expenses stood at $4.4 million in 2021, then tumbled by 46.99% to $2.3 million in 2022, then dropped by 16.03% to $2.0 million in 2023, then surged by 37.88% to $2.7 million in 2024, then dropped by 15.77% to $2.3 million in 2025.
  • Business Quant data shows Operating Expenses for INM at $2.3 million in Q4 2025, $2.2 million in Q3 2025, and $2.4 million in Q2 2025.